Page last updated: 2024-12-08

ketodihydrosphingosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

ketodihydrosphingosine: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-dehydrosphinganine : A 2-amino-1-hydroxyoctadecan-3-one that has S-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID439853
CHEBI ID17862
SCHEMBL ID188246
MeSH IDM0043680

Synonyms (20)

Synonym
3-ketodihydrosphingosine
(2s)-2-amino-1-hydroxyoctadecan-3-one
3-ketosphinganine
CHEBI:17862
LMSP01020002
C02934
3-dehydrosphinganine
3-dehydro-d-sphinganine
ketodihydrosphingosine
2-amino-1-hydroxy-3-octadecanone
18944-28-0
gtpl6654
SCHEMBL188246
kdhs
2-amino-1-hydroxy-octadecan-3-one
Q27073739
3-octadecanone, 2-amino-1-hydroxy-, (2s)-
'(2s,6e)-2-amino-1-hydroxyoctadec-6-en-3-one'
VSD ,
PD049907
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
2-amino-1-hydroxyoctadecan-3-one
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (21)

PathwayProteinsCompounds
Sphingolipid Metabolism2335
Gaucher Disease2335
Globoid Cell Leukodystrophy2335
Metachromatic Leukodystrophy (MLD)2335
Fabry Disease2335
Krabbe Disease2335
Biosynthesis of Unsaturated Fatty Acids1439
Biosynthesis of Unsaturated Fatty Acids (Tetracosanoyl-CoA)1435
Biosynthesis of Unsaturated Fatty Acids (Docosanoyl-CoA)1431
Biosynthesis of Unsaturated Fatty Acids (Icosanoyl-CoA)1427
Biosynthesis of Unsaturated Fatty Acids (Stearoyl-CoA)1322
Sphingolipid metabolism (integrated pathway)1167
Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway016
Sphingolipid metabolism overview415
Sphingolipid metabolism: integrated pathway163
Sphingolipid metabolism in senescence97
Synthesis of ceramides and 1-deoxyceramides115
sphingolipid metabolism020
Sphingolipid pathway315
Biochemical pathways: part I0466
Sphingolipids metabolism pathway063
Sphingolipid metabolism415
Lipid metabolism321

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (21.74)18.7374
1990's1 (4.35)18.2507
2000's10 (43.48)29.6817
2010's4 (17.39)24.3611
2020's3 (13.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.35%)6.00%
Case Studies1 (4.35%)4.05%
Observational0 (0.00%)0.25%
Other21 (91.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]